Want to see SE:ORGC full AI Analyst Report?
Top Page
OrganoClick AB
(ORGC)
Select Model
Select Model
Rating:41Neutral
Price Target:
kr0.23
▼(-87.13% Downside)
Action:Reiterated
Date:09/15/26
The score is driven primarily by weak financial performance—declining revenue, large ongoing losses, high leverage versus a small equity base, and continued (though moderating) cash burn. Technical indicators reinforce the downside risk, with the price below all major moving averages and negative MACD. Valuation is not a clear offset because the negative P/E reflects unprofitable operations and no dividend yield is provided.
Positive Factors
Bio-based chemistry platform
The company’s proprietary bio-based chemistry addresses multiple industrial treatment applications and aligns with the structural shift toward replacing fossil-based and hazardous inputs. This broadens potential customer use cases and supports durable relevance beyond any single product or end market.
Negative Factors
Declining revenue and deep losses
Falling revenue combined with deeply negative operating and net margins indicates that the current business model is not yet converting demand into sustainable profits. Continued losses can restrict reinvestment, weaken negotiating flexibility, and make recovery dependent on meaningful revenue or cost improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
Bio-based chemistry platform
The company’s proprietary bio-based chemistry addresses multiple industrial treatment applications and aligns with the structural shift toward replacing fossil-based and hazardous inputs. This broadens potential customer use cases and supports durable relevance beyond any single product or end market.
Read all positive factors
OrganoClick AB (ORGC) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr56.80M
Dividend YieldN/A
Average Volume (3M)230.11K
Price to Earnings (P/E)―
Beta (1Y)0.85
Revenue Growth-21.95%
EPS Growth-28.77%
CountrySE
Employees33
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-0.30
Shares Outstanding183,219,120
10 Day Avg. Volume150,006
30 Day Avg. Volume230,106
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)11.75
Price to Sales (P/S)1.68
P/FCF Ratio-16.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.13
Revenue Forecast (FY)kr113.00M
OrganoClick AB Business Overview & Revenue Model
Company Description
OrganoClick AB (publ), a technology firm based in Täby, Sweden, was established in 2006. The company specializes in the development, production, and sale of innovative fiber-based materials and chemicals for applications spanning wood treatment, t...
How the Company Makes Money
OrganoClick makes money primarily by selling products and chemical solutions based on its proprietary bio-based chemistry to industrial and consumer-facing markets. Key revenue streams include: (1) Sales of bio-based chemical products to industria...
OrganoClick AB Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
18
Very Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 90.28M | 106.19M | 127.23M | 145.87M | 115.05M | 110.06M |
| Gross Profit | 14.11M | 14.86M | 31.84M | 35.39M | 12.94M | 18.51M |
| EBITDA | -9.27M | -12.80M | 5.71M | 5.95M | -21.19M | -12.92M |
| Net Income | -32.19M | -36.37M | -17.97M | -15.77M | -41.62M | -31.03M |
Balance Sheet | ||||||
| Total Assets | 136.75M | 135.22M | 126.98M | 150.75M | 162.86M | 188.39M |
| Cash, Cash Equivalents and Short-Term Investments | 480.00K | 2.68M | 538.00K | 10.74M | 15.20M | 34.25M |
| Total Debt | 78.56M | 77.78M | 51.67M | 62.39M | 61.68M | 53.54M |
| Total Liabilities | 121.59M | 114.81M | 89.15M | 97.34M | 95.30M | 80.66M |
| Stockholders Equity | 10.53M | 15.18M | 28.98M | 44.58M | 58.78M | 100.33M |
Cash Flow | ||||||
| Free Cash Flow | -7.35M | -10.51M | -5.51M | -8.08M | -35.35M | -52.34M |
| Operating Cash Flow | -4.03M | -8.29M | 3.60M | 533.00K | -21.22M | -37.69M |
| Investing Cash Flow | -9.91M | -10.99M | -9.11M | -8.61M | -7.45M | -14.65M |
| Financing Cash Flow | 12.08M | 21.42M | -4.69M | 3.60M | 9.63M | 54.56M |
OrganoClick AB Technical Analysis
Negative
1.78
Price Trends
0.40
Negative
0.46
Negative
0.99
Negative
Market Momentum
-0.03
Positive
28.49
Positive
26.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ORGC, the sentiment is Negative. The current price of 1.78 is above the 20-day moving average (MA) of 0.35, above the 50-day MA of 0.40, and above the 200-day MA of 0.99, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 28.49 is Positive, neither overbought nor oversold. The STOCH value of 26.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ORGC.
OrganoClick AB Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | kr32.39B | 17.48 | 12.72% | 4.53% | -5.26% | -10.87% | |
63 Neutral | kr23.98M | 6.82 | ― | ― | -17.14% | 88.76% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
55 Neutral | kr146.11M | 49.75 | 1.04% | 6.75% | -14.23% | 84.80% | |
54 Neutral | kr302.36M | -16.04 | -8.17% | ― | -1.90% | -13.63% | |
47 Neutral | kr37.72M | -0.77 | -82.08% | 0.00% | -12.33% | 62.52% | |
41 Neutral | kr56.80M | -0.80 | -176.65% | ― | -21.95% | -28.77% |
* Basic Materials Sector Average
SE:ORGC
OrganoClick AB
0.22
-1.49
-87.16%
SE:HPOL.B
Hexpol AB
92.90
11.89
14.68%
SE:NEXAM
Nexam Chemical Holding AB
2.88
-1.00
-25.77%
SE:AERO
Svenska Aerogel Holding AB
0.74
-1.01
-57.58%
SE:POLYG
Polygiene AB
3.97
-4.81
-54.76%
SE:PCAT
Photocat A/S
4.00
-3.50
-46.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.